# US 2024/0197710 A1 · Modified release nicorandil compound formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197710 A1
- Document ID: US20240197710A1
- Status: Published application
- Kind: A1
- Application number: 18/408,490
- Filed: 2024-01-09
- Published: 2024-06-20
- Earliest claimed: 2021-07-10
- Applicants: Auxilius Pharma Spolka Z Ograniczona Odpowiedzialnoscia
- Inventors: Denny Johan Marijn Van Den Heuvel; Johannes Jan Platteeuw; Uwe Tigor; Dawid Sebastian Chabowski
- Web page: https://patentgrep.com/patent/US20240197710A1

## CPC

- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61J 1/035: {Blister-type containers (blisters in general B65D75/36)}
- A61J 1/1468: {Containers characterised by specific material properties}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are compositions comprising nicorandil compound(s) in a controlled release formulation that releases at least about 30% of the nicorandil compound(s) into the intestine of human subjects. Such compositions can include a gastric acid dissolution susceptible component (GADSC) and a gastric acid dissolution resistant component (GADRC), wherein upon maintaining the composition in contact with a pH 1.2 dissolution media for a period of about 2 hours (1) the GADRC releases a statistically significantly smaller proportion of the one or more nicorandil compounds in the GADRC than the proportion of one or more nicorandil compounds release from the GADSC and (2) the composition releases no more than 50% of the one or more nicorandil compounds contained in the composition. The invention further provides methods of product such compositions and therapeutic uses of compositions, e.g., comprising once-daily administration of the composition to treat one or more diseases or conditions, including angina.

## Claims

### Claim 1

A pharmaceutically acceptable composition comprising a therapeutically effective amount of nicorandil contained in a controlled release formulation comprising a controlled release gastric acid dissolution susceptible component comprising a release retardant polymer component and a controlled release gastric acid dissolution resistant component comprising both a release retardant polymer component and a pH responsive release resistant polymer component, wherein (1) upon maintaining the composition in contact with a pH 1.2 dissolution media for a period of 4 hours the composition releases no more than 50% of the nicorandil contained in the composition, (2) the gastric acid dissolution susceptible controlled release component (a) comprises a first part of the therapeutically effective amount of the nicorandil, (b) releases (i) between 11% to 28% of the nicorandil initially present in the gastric acid dissolution susceptible component after 0.25 hours in the dissolution media of pH 1.2; (ii) 35% to 50% of the nicorandil initially present in the gastric acid dissolution susceptible component after 1 hour in the dissolution media of pH 1.2; (iii) 55% to 70% of the nicorandil initially present in the gastric acid dissolution susceptible component after 2 hours in the dissolution media of pH 1.2; and (iiii) 80-100% of the nicorandil initially present in gastric acid dissolution susceptible component 6 hours after contact with the dissolution media having a pH of about 1.2, (3) the gastric acid dissolution resistant component (a) comprises a second part of the therapeutically effective amount of the nicorandil and (b) releases no more than 20% of the nicorandil contained in the gastric acid dissolution resistant component after 6 hours of contact with a dissolution media having a pH of 1.2, and (4) the amount of the nicorandil in the first part of the therapeutically effective amount and the amount of the nicorandil in the second part of the therapeutically effective amount differ by less than about 10%, and wherein the first part comprises 30-70% of the nicorandil in the composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein (1) the gastric acid dissolution susceptible component comprises a matrix formulation comprising 25-45% of a release retardant polymer component and 40-70% of a binder component, (2) the gastric acid dissolution resistant component comprises a matrix formulation comprising 25-45% of a release retardant polymer component and 40-70% of a binder component, or (3) the gastric acid dissolution susceptible component comprises a matrix formulation comprising 25-45% of a release retardant polymer component and 40-70% of a binder component, and the gastric acid dissolution resistant component comprises a matrix formulation comprising 25-45% of a release retardant polymer component and 40-70% of a binder component.

### Claim 3 (depends on 2)

The composition of claim 2, wherein (1) the release retardant polymer component and the nicorandil in the gastric acid dissolution susceptible component are present in a ratio of 2:1 to 5:1, (2) the release retardant polymer component and the nicorandil in the gastric acid dissolution resistant component are present in a ratio of 2:1 to 5:1, or (3) the release retardant polymer component and the nicorandil in the gastric acid dissolution susceptible component are present in a ratio of 2:1 to 5:1 and the release retardant polymer component and the nicorandil in the gastric acid dissolution resistant component are present in a ratio of 2:1 to 5:1.

### Claim 4 (depends on 2)

The composition of claim 2, wherein (1) 40-65% of the gastric acid dissolution susceptible component is composed of a binder component, (2) 40-65% of the gastric acid dissolution resistant component is composed of a binder component, or (3) 40-65% of the gastric acid dissolution susceptible component is composed of a binder component and 40-65% of the gastric acid dissolution resistant component is composed of a binder component.

### Claim 5 (depends on 4)

The composition of claim 4, wherein (1) the binder component and the nicorandil are present in a ratio of about 4:1 to about 7:1 in the gastric acid dissolution susceptible component, (2) the binder component and the nicorandil are present in a ratio of about 4:1 to about 7:1 in the gastric acid dissolution resistant component, or (3) the binder component and the nicorandil are present in a ratio of about 4:1 to about 7:1 in the gastric acid dissolution susceptible component and the binder component and the nicorandil are present in a ratio of about 4:1 to about 7:1 in the gastric acid dissolution resistant component.

### Claim 6 (depends on 1)

The composition of claim 1, wherein most of the excipients in the composition have a moisture content of less than 6%.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the gastric acid dissolution susceptible component comprises 2-5 gastric acid dissolution susceptible component dosage forms and the gastric acid dissolution resistant component comprises 2-5 gastric acid dissolution resistant component dosage forms, wherein gastric acid dissolution susceptible dosage forms and the gastric acid dissolution resistant dosage forms are contained in a pharmaceutically acceptable capsule.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the therapeutically effective amount is 15-75 mg of nicorandil.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the nicorandil is the only active pharmaceutical ingredient of the composition.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the nicorandil is the only active pharmaceutical ingredient of the composition.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the gastric acid dissolution susceptible component comprises 2-5 gastric acid dissolution susceptible component dosage forms and the gastric acid dissolution resistant component comprises 2-5 gastric acid dissolution resistant component dosage forms, wherein gastric acid dissolution susceptible dosage forms and the gastric acid dissolution resistant dosage forms are contained in a pharmaceutically acceptable capsule.

### Claim 12 (depends on 1)

A pharmaceutical product comprising the pharmaceutical composition of claim 1 packaged in an aluminum blister pack, the aluminum blister pack further containing an effective amount of a pharmaceutically acceptable desiccant.

### Claim 13 (depends on 7)

A pharmaceutical product comprising the pharmaceutical composition of claim 7 packaged in an aluminum blister pack, the aluminum blister pack further containing an effective amount of a pharmaceutically acceptable desiccant.

### Claim at position 14

-20. (canceled)
